The Rxponder Trial And Its Impact On Best Clinical Practice

The RxPONDER trial and its impact on best clinical practice

The RxPONDER trial and its impact on best clinical practice ecancer Google Chrome 2021 12 23 20

Χρήστος Μαρκόπουλος

RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

Race and clinical outcomes in the RxPONDER trial

RxPONDER: 21-gene assay informs chemotherapy benefit in HR+ node-positive breast cancer

Kalinsky discusses results from RxPONDER breast cancer clinical trial

Winship Cancer Institute of Emory University

What are the implications for practice with the RxPonder data?

Oncotype DX Breast Recurrence Score Assay after TAILORx and RxPONDER: What’s Next?

אונקוטסט

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

SABCS highlights: RxPONDER

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020

27 Principles of Clinical Trials

Hope For Stomach Cancer

Case Discussions - Early Stage and Metastatic | 2023 COEDS Discussion Series Fort Lauderdale

Total Health | Oncology

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium

Should I Participate In a Cancer Clinical Trial?

Yerbba – Breast Cancer

DEBATE: RxPONDER: "Was it all OFS?" Pro

San Antonio Breast Cancer Symposium

Race, Ethnicity, and Clinical Outcomes From the TAILORx Trial

RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

DEBATE: "RxPONDER: Was it all OFS?" Con

San Antonio Breast Cancer Symposium

Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER